Zusammenfassung
Die Osteoporose wird heute zu den 10 wichtigsten Volkskrankheiten gezählt und verursacht allein in Deutschland Kosten in Milliardenhöhe. In den letzten 15 Jahren haben Fortschritte in der Diagnostik und in der Entwicklung neuer Medikamente dazu geführt, dass die Osteoporose als vermeidbare bzw. behandelbare Volkskrankheit anerkannt wird. Trotz dieser enormen Fortschritte ist die Osteoporose aber immer noch eine untertherapierte Krankheit. So werden in Deutschland nur etwa 10–15% der Patienten mit manifester Osteoporose leitliniengerecht behandelt. Mit dieser mangelhaften Versorgung werden Kosten in Milliardenhöhe und Leid der Betroffenen unnötigerweise in Kauf genommen. In Ergänzung zu den nationalen Leitlinien liegt jetzt ein europäisches Positionspapier zum Management der Osteoporose in Neuauflage vor, das den behandelnden Ärzten weitere Sicherheit in der Behandlung von Osteoporosepatienten gibt. Schwerpunkte liegen in einer fraktur- und kostenorientierten Beurteilung der Therapie von Patienten mit Osteoporose.
Abstract
Osteoporosis is one of the ten most important and widespread global diseases. In Germany alone the costs of osteoporosis run into billions of Euros. However, during the past 15 years great progress has been made both in diagnosis and in the development of new medications. Osteoporosis is now taken very seriously and recognized as a national and global disorder which is now both preventable and treatable. Nevertheless, at a practical level, both in Europe and especially in Germany, osteoporosis remains an underdiagnosed and undertreated disease. In Germany, only about 10–15% of patients with manifest osteoporosis are properly treated. The consequences of such inadequate care are high additional costs—not to mention the unnecessary suffering of the patients involved. However, in support of national guidelines, a new edition of the “European Position Paper for the Diagnosis and Management of Osteoporosis” provides the doctors who treat patients with osteoporosis with additional information and therefore more confidence. In this paper several aspects are emphasized: improvements in diagnostic evaluation, assessment of the efficacy of fracture-oriented medications, and cost-effectiveness of the treatment of patients with osteoporosis.
Literatur
Bartl R (2002) Osteoporose: Was ist gesichert in der Therapie? Internist 43: 1529–1543
Bartl R (2007) Leitliniengerechtes Management der Osteoporose: Rationell – kostensparend – effektiv. Dtsch Med Wochenschr 132: 995–999
Bartl R (2008) Osteoporose – Prävention, Diagnostik, Therapie, 3. Aufl. Thieme, Stuttgart
Bartl R, Bartl C, Mutschler W (2003) Diagnostik und Therapie der Osteoporose: Strategie für eine effiziente Prävention von Folgefrakturen. Unfallchirurg 106: 526–541
Bartl R, Frisch B, Tresckow E von, Bartl C (2007) Bisphosphonates in medical practice. Springer, Berlin Heidelberg New York
Bartl R, Thaler C (2007) Leitliniengerechte Diagnostik und Therapie der postmenopausalen Osteoporose – eine neue Verantwortung für den Gynäkologen. Gynakologe 40: 913–923
Black DM, Delmas PD, Eastell R et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822
Black DM, Schwartz AV, Ensrud KE et al.; FLEX Research Group(2006) Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927–2936
Burge R, Dawson-Hughes B, Solomon D et al. (2007) Incidence and economic burden of osteoporostic-related fractures in the United States. 2005–2025. J Bone Miner Res 22: 465–475
Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17: 1638–1644
Cranney A, Guyatt G, Griffith L et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570–578
Cummings SR, Karpf DB, Harris F et al. (2006) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281–289
Delmas P, Rizzoli R, Cooper C (2005) Treatment of patients with postmenopausal osteoporosis is worthwile. The position of the International Osteoporosis Foundation. Osteoporos Int 16: 1–5
Häussler B, Gothe H, Mangiapane S et al. (2006) Versorgung von Osteoporose-Patienten in Deutschland. Ergebnisse der BoneEVA-Studie. Dtsch Arztebl 39: B2199–B2205
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17: 1726–1733
Johnell O, Oden A, De Laet C et al. (2002) Biochemical markers and the assessment of fracture probability. Osteoporos Int 13: 523–526
Kanis J, Burlet N, Cooper C et al. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal osteoporosis. Osteoporos Int 19: 399–428
Kanis JA, Adams J, Borgström F et al. (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42: 4–15
Kanis J, Johnell O, Oden A et al. (2005) Intervention threshholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16: 6–14
Kanis JA, Oden A, Johnell O et al. (2003) The components of excess mortality after hip fracture. Bone 32: 468–473
Lyles KW, Colon-Emeric CS, Magaziner JS et al. the HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809
Pazianas M, Blumentals W, Miller P (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19: 773–778
Rabenda V, Mertens R, Fabri V et al. (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19: 811–818
Reginster JY, Rabenda V (2006) Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol 1: 37–40
Russell R, Watts N, Ebentino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733–759
Siris E, Chen Y, Abbott T et al. (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164: 1108–1112
Zethraeus N, Ström O, Borgström F et al. (2008) The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. Osteoporos Int 19: 819–827
Interessenkonflikt
Der Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt wird, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bartl, R. Therapie der Osteoporose nach der „European Guidance 2008“. Internist 49, 1126–1136 (2008). https://doi.org/10.1007/s00108-008-2192-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-008-2192-y